Feasibility of bystander-administered naloxone delivered by drone to opioid overdose victims.

Am J Emerg Med

VCU Health, Department of Emergency Medicine, PO Box 980401, Richmond, VA 23298, United States of America; VCU Health, Department of Internal Medicine (Cardiology), PO Box 980036, Richmond, VA 23298, United States of America. Electronic address:

Published: September 2020

Background: Currently, ≤5% of bystanders witnessing an opioid overdose (OD) in the US administer antidote to the victim. A possible model to mitigate this crisis would be a system that enables 9-1-1 dispatchers to both rapidly deliver naloxone by drone to bystanders at a suspected opioid OD and direct them to administer it while awaiting EMS arrival.

Methods: A simulated 9-1-1 dispatcher directed thirty subjects via 2-way radio to retrieve naloxone nasal spray from atop a drone located outside the simulation building and then administer it using scripted instructions. The primary outcome measure was time from first contact with the dispatcher to administration of the medication.

Results: All subjects administered the medication successfully. The mean time interval from 9 -1-1 contact until antidote administration was 122 [95%CI 109-134] sec. There was a significant reduction in time interval if subjects had prior medical training (p = 0.045) or had prior experience with use of a nasal spray device (p = 0.030). Five subjects had difficulty using the nasal spray and four subjects had minor physical impairments, but these barriers did not result in a significant difference in time to administration (p = 0.467, p = 0.30). A significant number of subjects (29/30 [97%], p = 0.044) indicated that they felt confident they could administer intranasal naloxone to an opioid OD victim after participating in the simulation.

Conclusions: Our results suggest that bystanders can carry out 9-1-1 dispatcher instructions to fetch drone-delivered naloxone and potentially decrease the time interval to intranasal administration which supports further development and testing of a such a system.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajem.2020.05.103DOI Listing

Publication Analysis

Top Keywords

nasal spray
12
time interval
12
opioid overdose
8
9-1-1 dispatcher
8
subjects
6
naloxone
5
time
5
feasibility bystander-administered
4
bystander-administered naloxone
4
naloxone delivered
4

Similar Publications

Background: Posterior nasal nerve (PNN) cryoablation improves chronic rhinitis (CR) symptoms in 70-80% of cases, including clear thin rhinorrhea (CTR). This study's purpose was to determine time to and degree of CTR recurrence following cryoablation.

Methods: A multicenter retrospective cohort study was conducted on patients who underwent PNN cryoablation to treat CR-related CTR refractory to ipratropium bromide nasal spray (IBNS).

View Article and Find Full Text PDF

Background: Migraine is a disabling disorder that impacts 40 million people in the US. Zavegepant is the first calcitonin gene-related peptide (CGRP) receptor antagonist nasal-spray approved for the acute treatment of migraine with or without aura in adults. This study aimed to evaluate the proportion of patients in various pain and functional disability states over 48-h, for patients treated with zavegepant 10 mg nasal-spray versus placebo.

View Article and Find Full Text PDF

Background: The success rate of chronic rhinitis surgery varies depending on the patients' factor and surgical method. While outcomes for nasal obstruction differ, the association between preoperative severity of other rhinitis symptoms, such as rhinorrhea, sneezing, and nasal itching, measured via the reflective total nasal symptom score (rTNSS) remains unevaluated.

Objective: To evaluate the association between the response rate to surgical treatment of chronic rhinitis and preoperative severity.

View Article and Find Full Text PDF

A randomized comparison of bencycloquidium bromide, mometasone furoate and a combination for persistent allergic rhinitis.

J Allergy Clin Immunol Pract

December 2024

Department of Allergy, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China; Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China; Beijing Laboratory of Allergic Diseases and Beijing Key Laboratory of Nasal Diseases, Beijing Institute of Otolaryngology, Beijing 100005, China. Electronic address:

Background: Moderate to severe persistent allergic rhinitis (AR) poses a substantial socioeconomic burden.

Objectives: We aimed to establish the superiority of bencycloquidium bromide (BCQB) nasal spray and BCQB combined with mometasone furoate nasal spray (MFNS) over MFNS alone in adults with moderate-to-severe persistent AR.

Methods: In this multicentre, randomised controlled clinical trial (NCT05038202), adults with moderate-to-severe persistent AR were randomly assigned to receive the BCQB, MFNS, or a combination treatment, for 4-week periods.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!